Companies: 10,795·Total market cap: $144.5T
Vyome Holdings, Inc.

Vyome Holdings, Inc.

HINDNASDAQHealthcare● Active
$2.19
+$0.03(+1.39%)
Market Cap$12330815
P/E Ratio
52W High$20.76
52W Low$1.75

Vyome Holdings, Inc. (HIND) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

hind · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Vyome Holdings, Inc. (HIND) measures how much investors pay for each dollar of the company's trailing earnings. HIND's current PE ratio of N/A is calculated by dividing its stock price of $2.19 by its TTM earnings per share of -$2.24.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-0.92
Based on 1 analyst
EPS (TTM)
-$2.24
TTM · diluted EPS
PEG Ratio
-0.01
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vyome Holdings, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2006 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Vyome Holdings, Inc.
Vyome Holdings, Inc.You
HIND
$12MN/A-$2.24
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.
ARMP
$278MN/A-$4.80
C4 Therapeutics, Inc.
C4 Therapeutics, Inc.
CCCC
$297MN/A-$1.27
Codexis, Inc.
Codexis, Inc.
CDXS
$237MN/A-$0.50
Compugen Ltd.
Compugen Ltd.
CGEN
$193M4.04x$0.38
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc.
IMDX
$154MN/A-$1.65
Innate Pharma S.A.
Innate Pharma S.A.
IPHA
$165MN/A-$0.55

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-4.75
2024-12-31
FY2024
$-345.75
2023-12-31
FY2023
$-2772.58
2022-12-31
FY2022
$-157897.92
2021-12-31
FY2021
$-419004.49
2020-12-31
FY2020
$-503023.26
2019-12-31
FY2019
$-3429105.09
2018-12-31
FY2018
$-9271816.62
2017-12-31
FY2017
$-4399927.14
2016-12-31
FY2016
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Vyome Holdings, Inc. (HIND) measures how much investors pay for each dollar of the company's trailing earnings. HIND's current PE ratio of N/A is calculated by dividing its stock price of $2.19 by its TTM earnings per share of -$2.24.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.19 ÷ -$2.24 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

HIND pe ratio · 6 questions

HIND's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.19 and TTM EPS of -$2.24. Data sourced from Financial Modeling Prep via HIND's SEC 10-K and 10-Q filings.

HIND PE ratioWhat is HIND PE ratioCurrent PE ratio of HINDHIND PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vyome Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08